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1999) or the components of the IL-31
receptor might be involved in the
pathogenesis of sporadic PCA.
Although additional work is required to
translate our current finding to disease
management, modulation of MCP-1
level and function, through IL-31-
dependent and -independent pathways,
may offer a new approach for
therapeutic development for FPCA.
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Usefulness of Immunocytochemistry for the Detection
of the BRAFV600E Mutation in Circulating Tumor Cells
from Metastatic Melanoma Patients
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TO THE EDITOR
Metastatic melanoma patients harboring
a BRAF gene mutation on codon 600
can be treated with targeted therapies
(Flaherty, 2012). Depending on the
content of tumor cells and on the
analytical sensitivity, BRAF mutations
are found in 50–70% of metastatic
melanoma patients (Davies et al.,
2002). Around 80% display a valine-
to-glutamic acid substitution (V600E)
and B16% harbor a valine-to-
lysine substitution (V600K) causing
constitutive kinase activation (Wan
et al., 2004; Rubinstein et al., 2010).
BRAFV600E mutation analysis is currently
performed in daily clinical practice on
tissue samples using various molecular
biology technologies. Moreover, the
detection of the BRAFV600E mutation in
blood samples from melanoma patients
in the context of translational research
and clinical trials has been des-
cribed (Board et al., 2009; Sakaizawa
et al., 2012). Metastatic dissemination
Abbreviations: CMCs, circulating melanoma tumor cells; CTCs, circulating tumor cells; ICC,
immunocytochemistry; IHC, immunohistochemistry; ISET, isolation by size of epithelial tumor cells
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correlates with the presence of
circulating tumor cells (CTCs) detected
in blood samples (Paterlini-Brechot
et al., 2011; Alix-Panabie`res et al.,
2012). The detection of circulating
melanoma tumor cells (CMCs) can be
performed using different technologies,
in particular by the isolation by size
of epithelial tumor cells (ISET) method,
a direct method that allows cyto-
pathological analysis of CMCs (De
Giorgi et al, 2010). Moreover, ancillary
methods for CTC characterization can
be performed on cells isolated by ISET
(De Giorgi et al., 2010; Ilie et al., 2012).
Recent studies highlighted the value
of immunohistochemistry (IHC) using
the VE1 antibody for the detection of
the BRAFV600E mutation in melanoma
(Capper et al., 2012). The aim of this
work was to combine ISET and
immunocytochemistry (ICC) using
the VE1 antibody to investigate the
presence of BRAFV600E in CMCs from
metastatic melanoma patients.
Therefore, 98 metastatic melanoma
patients were screened for BRAFV600E
both by pyrosequencing and by IHC
anti-VE1. Concomitantly and blindly,
ICC for the BRAF mutation was per-
formed on CMCs isolated by ISET (See
Supplementary Data). Population data
are shown in Supplementary Table S1.
Of 98 patients, 53 (54%) had a
BRAFV600E mutation detected by pyro-
sequencing in tissue samples. Among
these patients, 51/53 (96%) showed
strong immunostaining with the
VE1 antibody in tissue sections
(Supplementary Table S2). Homogenous
intracytoplasmic staining without asso-
ciated nuclear staining was demon-
strated in melanoma cells only
(Figure 1). Among the tumors negative
for the BRAF mutation by pyrosequen-
cing, none had positive VE1 immunos-
taining (Supplementary Table S2;
Figure 1). An excellent concordance
was found between these two methods
(Supplementary Table S2). The IHC anti-
VE1 demonstrated 96% sensitivity and
100% specificity when compared with
the sequencing results. CMCs were iso-
lated in 87/98 (89%) patients. Of 87
patients, 54 (62%) demonstrated posi-
tive immunostaining on ISET filters as
detected by VE1 ICC (Table 1; Figure 1).
Forty-six out of fifty-four (85%) patients
with CMCs positively stained by ICC
had a BRAFV600E mutation detected
in tissue specimen by pyrosequencing
(Table 1; Figure 1). Eight out of fifty-four
(15%) patients with positive VE1-immu-
nostained CMCs lacked BRAFV600E in
tumor tissues, analyzed both by pyrose-
quencing and IHC (Table 1; Figure 1).
The ICC VE1 CMC-based assay
revealed 100% sensitivity and 81%
specificity when compared with the
pyrosequencing results on the corre-
sponding tumor specimens. Among the
87 patients with CMCs isolated by ISET,
5 had BRAFV600K mutation in melanoma
tissue, without positive staining with the
VE1 antibody, both in tissue sections
and in CMCs (Figure 1). Control immu-
nostaining on CMCs using anti-CD45
was negative (not shown).
This study shows that CMCs isolated
by ISET can be used to detect the
BRAFV600E mutation in patients with
advanced melanoma by using the VE1
antibody. We demonstrated that this
noninvasive approach is highly sensitive
and relatively specific for the detection
of BRAFV600E in CMCs, having high
level of concordance with results in
tissue samples. In comparison with
other approaches used for the detection
of BRAFV600E from blood samples, ISET
allows cytopathological detection of
CMCs before the analysis for a mutation,
affording correlation of cytomorphologi-
cal and ICC data and avoiding interpre-
tation bias (Paterlini-Brechot et al.,
2007). Moreover, ISET is a rapid and
low-cost method that can easily be
repeated, thereby allowing the
monitoring of CMC detection in
patients on targeted therapy. The use
of ICC for the detection of the
BRAFV600E mutation on CMCs has
advantages, but also a few potential
drawbacks. Interestingly, eight patients
included in the present series showed
CMCs positively stained by ICC using
the VE1 antibody, whereas BRAFV600E
was not found in the corresponding
tumor tissue samples. As molecular
heterogeneity is a common event in
tumors, it is possible that the tissue
sample used for both pyrosequencing
and IHC analysis may not harbor the
BRAFV600E mutation (Longo, 2012). In
these cases, BRAFV600E-mutated CMCs
derived from other parts of the tumor
would have invaded the blood stream,
initiating metastatic dissemination.
Second, even if pyrosequencing is a
sensitive technology (B5%), the
presence of a small amount of mutated
cells in the tissue sample may give a
false negative result (Gonzalez de Castro
et al., 2012). It has been described
previously that VE1 immunostaining
may be useful for the detection of
smaller amounts of BRAFV600E-mutated
cells in tissue sections (Capper et al.,
2012). The hypothesis of a false positive
ICC result on CMCs can be reasonably
eliminated, as negative controls made in
parallel on CMCs isolated by ISET did
not show any staining. Future
developments on the investigation of
the BRAFV600E mutation in CMCs
isolated by ISET, both by ICC and DNA
sequencing, should add more
information to this issue. For now, the
low number of detected CMCs (from two
to eight CMCs) in these eight patients did
not allow us to obtain conclusive results
by pyrosequencing performed on
Table 1. Correlation between the mutational status of the BRAF gene
detected by pyrosequencing on tumor specimens and BRAFV600E expression
detected by ICC with the VE1 antibody on circulating melanoma cells
isolated by ISET from 87 metastatic melanoma patients
ICC anti-VE1, n (%)
Pyrosequencing (n) Positive Negative j-Index P-value1
V600E (46) 46 (85%) 0 (0%) 0.62 o0.001
V600K (5) 0 (0%) 5 (15%)
Wild-type (36) 8 (15%) 28 (85%)
Overall 54 (62%) 33 (38%)
Abbreviations: ICC, immunocytochemistry; ISET, isolation by size of epithelial tumor cells.
1A w2 test was used. P-value significant at the 0.05 level.
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extracted DNA from CMCs. Larger
studies are now needed to determine
whether the detection of BRAFV600E in
CMCs using VE1 immunostaining could
allow the selection of patients for a
targeted therapy, despite the absence of
detection in tissue sample. In conclu-
sion, CMCs can be detected by ISET in
patients with advanced melanoma, and
can be analyzed by using ICC with the
VE1 antibody for the identification of the
BRAFV600E mutation in melanoma cells.
This approach is noninvasive, rapid, very
sensitive, and specific, and opens new
options for taking care of metastatic
melanoma patients in the era of
innovative targeted treatments.
All patients enrolled in the study
provided written, informed consent.
The study was approved by the Ethics
Committee of the Nice University Hos-
pital Centre and was performed in
adherence to the Helsinki Guidelines.
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Figure 1. Immunochemical features of BRAFV600E- or BRAFV600K-mutated tumors and BRAF wild-type
tumors. (Case no. 1) BRAFV600E-mutated metastatic melanoma demonstrating positive immunostaining
with the VE1 antibody on both (a) a tumor specimen and (b) circulating melanoma cells detected by
isolation by size of epithelial tumor cells (ISET). (Case no. 2) BRAF wild-type metastatic melanoma showing
no staining with the VE1 antibody on both a tumor specimen (c) and (d) circulating melanoma cells. (Case
no. 3) BRAFV600E-mutated metastatic melanoma displaying negative immunostaining with the VE1 clone
on the tumor tissue (e) and (f) intense positive cytoplasmic staining on the circulating melanoma cells
detected by ISET. (Case no. 4) BRAFV600K-mutated metastatic melanoma demonstrating negative
immunostaining with the VE1 antibody on both a tumor specimen (g) and (h) circulating melanoma cells
isolated by ISET. Right figures, immunoperoxidase, original magnification  200; left figures,
immunoperoxidase, original magnification 1,000; scale bar¼ 16mm.
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TO THE EDITOR
In the wake of new treatments for
advanced melanoma (Chapman et al.,
2011; Robert et al., 2011), the
identification of novel blood biomar-
kers to monitor therapeutic response
and disease recurrence is timely.
MicroRNAs (miRNAs) are promising
because they can be assayed directly
from blood. Over 1,000 of these exist
(Griffiths-Jones et al., 2008) showing
alterations in both cancer tissue (Calin
et al., 2002) and blood (Mitchell et al.,
2008). MiR-21 is one of the most widely
studied and is upregulated in many
cancers (Volinia et al., 2006). In
melanoma, its genetic locus shows
gains (Zhang et al., 2006), and in
histologically ambiguous melanocytic
lesions it is associated with sentinel
lymph node status (Grignol et al.,
2011) and correlates with prognosis
(Jiang et al., 2011). Our hypothesis was
that plasma miRNAs are biomarkers of
melanoma burden. We used miR-21 as
a proof of concept to test this because it
has been widely studied in cancer.
We analyzed 160 melanocytic tumors
(Supplementary Table S1 online) and 56
blood samples. First, miR-21 expression
was measured in 51 melanomas using
quantitative PCR, finding a significant
association with Breslow thickness and
ulceration, two important prognostic
features (Balch et al., 2009), P¼0.02,
0.024, respectively, Supplementary
Table S2 online. To assess inde-
pendent prognostic value, another set
of 79 melanomas was analyzed
(Supplementary Table S1 online), 40
having disease-free survival 45 years
and 39 having metastasis within 5 years.
Logistic regression showed that the stage
(IB/IIA versus IIB/IIC) and miR-21
(dichotomized at median) both signifi-
cantly predicted progression-free survi-
val with an odds ratio of 4.83
(confidence interval (CI), 1.79–13.04),
P¼0.002 and 2.72 (CI, 1.01–7.34),
P¼0.048, respectively. The covariates
explained between 16 and 21% of the
total variation (Cox and Snell R2 and
Nagelkerke R2, respectively). The addi-
tion of miR-21 to the American Joint
Committee on Cancer (AJCC) stage
increased the model accuracy (w2¼4.10,
d.f.¼1, P¼ 0.043). These data suggest
that tissue miR-21 has independent
prognostic value. We next assessed miR-
21 expression during tumor progression
in 51 melanomas, 13 common nevi,
and 11 congenital nevi using cultured
melanocytes as calibrator (Figure 1a).
Expression was significantly different
(F¼ 5.65, d.f.¼2, P¼0.005). Post hoc
analysis revealed a trend of increasing
expression from common nevi and con-
genital nevi to melanoma (F¼11.05,
d.f.¼1, P¼0.001). Colorimetric in situ
hybridization confirmed tumor cell
expression (Figure 1b–d). The relatively
high expression in congenital nevi is
intriguing, perhaps reflecting their
increased risk of progressing to mela-
noma (Krengel et al., 2006). These
data fit well with recently reported
data in melanoma tissues and cell lines
(Satzger et al., 2012). We next looked at
whether miR-21 expression in meta-
static tumor tissue related to plasma
levels, finding a strong correlation,
n¼5, r¼0.997, P¼0.0002 (Figure 2a).
These data confirm that miR-21 is an
important tissue biomarker in melanoma
and that tissue expression reflects plasma
level.
We then looked at whether plasma
miR-21 correlated with melanoma
burden measured by the AJCC stage.
We collected blood from 18 patientsAbbreviations: AJCC, American Joint Committee on Cancer; CI, confidence interval; miRNA, microRNA
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